Skip to main content
NEXTBIOMEDICAL Co., Ltd. logo

NEXTBIOMEDICAL Co., Ltd. - Investor Relations & Filings

Listed IPO Aug 2024
Ticker · 389650 ISIN · KR7389650003 KO Manufacturing
Open in API
Filings indexed 61 across all filing types
Latest filing 2026-06-25 Director's Dealing
Country KR South Korea
Listing KO 389650 · 1 venue

About NEXTBIOMEDICAL Co., Ltd.

https://nextbiomedical.co.kr/en/

NEXTBIOMEDICAL Co., Ltd. is a company specializing in the development and commercialization of innovative therapeutic solutions, with a focus on drug-device combination products. The company's core competency is its proprietary polymer technology platform, which includes biodegradable adhesive polymers and resorbable microspheres. These technologies are applied to create first-in-class medical devices that address unmet clinical needs. Key product applications include advanced hemostatic agents for endoscopic procedures and embolic materials for interventional pain management and vascular therapies, such as genicular artery embolization for osteoarthritis pain.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주특정증권등소유상황보고서). This is a standard regulatory filing in South Korea (often filed with the Financial Supervisory Service) that discloses personal share transactions (insider trading) by company directors or major shareholders. Based on the provided filing definitions, this falls under 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives.
2026-06-25 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주특정증권등소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the acquisition of shares by a company executive (Kang Cheol-jung) of Next Biomedical. This is a standard regulatory filing in South Korea (DART system) for reporting insider transactions, which corresponds to the 'Director's Dealing' category.
2026-06-22 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is an ownership report filed by a company executive (an officer) disclosing specific securities owned and changes therein, submitted to the securities regulator and stock exchange. This matches insider share dealings by a director/executive. Therefore, it falls under Director's Dealing (DIRS).
2026-05-26 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 92% confidence The document is titled “분기보고서” (Korean for “Quarterly Report”) and covers the fiscal period from January 1, 2026 to March 31, 2026, with detailed business overview, corporate history, share capital, and extensive narrative and tabular data typical of an interim/quarterly financial report. It is not merely a notice of publication, an earnings release, or a management presentation. Therefore, it is classified as an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' which translates to 'Report on Ownership Status of Specific Securities by Executives and Major Shareholders.' It includes detailed information about the ownership of securities by an individual named 한명식, who is a non-registered executive of the company 넥스트바이오메디컬. The document contains specifics such as the number of shares owned, ownership percentages, and changes in ownership due to appointment as a non-registered executive. This type of report corresponds to insider share transactions or holdings by directors and executives. Therefore, it fits the category of Director's Dealing (DIRS). The document length is 2499 characters, which is consistent with a detailed insider transaction report rather than a brief announcement or a full financial report.
2026-05-07 Korean
투자판단관련주요경영사항 (NexsphereF 일본 독점 판권 계약)
Regulatory Filings Classification · 70% confidence The document is a corporate disclosure in Korean titled “투자판단 관련 주요경영사항” describing a licensing/distribution agreement (Nexsphere-F™ Japan exclusive rights) with Asahi Intecc. It is not an AGM material, annual or interim report, audit or earnings release, nor is it about dividends, board changes, share issues, M&A, or insider trades. It is a standalone announcement of a major contract that does not fall under financing, share transactions, or any other defined specific category. Therefore, it is classified under the fallback “Regulatory Filings” (RNS).
2026-04-09 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.